Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

300 Third Street, 3rd Floor, Cambridge, MA, 02142, USA

Type of Company

Public

Employees (Worldwide)

1,065

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Alnylam Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President

Chief Financial & Accounting Officer

Executive Vice President & Chief Operating Officer

Chief Information Officer & Senior Vice President

Chief Medical Officer

Executive Vice President, Chief Legal Officer & Secretary

Chief Human Resource Officer

Vice President, Associate General Counsel

President-Research & Development

Board of Directors

Executive Chairman at Kaleido Biosciences, Inc.

Co-Founder at REPLIGEN Corp.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Co-Founder at Lyndra Therapeutics, Inc.

President at International Council of Ophthalmology Foundation

Foreign Secretary at National Academy of Medicine

Co-Founder at Center For Assessment Technology & Continuous Health

Co-Founder at Tal Medical, Inc.

Former Executive Vice President & Chief Operating Officer at Health Care Service Corp.

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Paths to Alnylam Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Alnylam Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm's investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford's analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

Maverick's investment process is driven by intensive, fundamental bottom-up research. They do not attempt to time the markets or focus on weightings relative to any index. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. Maverick's investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by five discipline research teams: credit, private equity, quantitative, Asia and small-cap investments.

Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Recent Transactions
Details Hidden

Alnylam Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Escrow Agent

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Chair, Life Sciences Practice

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onAlnylam Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Legal Advisor

Co-Chair, Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Clients

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2018
Market Capitalization
$13.2B
Total Enterprise Value
$6.28B
Earnings Per Share
$-7.57
Revenue
$74.9M
Net Profit
$-762M
EBITDA
$-808M
EBITDAMargin
-1,078.97%
Total Debt
$30M
Total Equity
$1.3B
Enterprise Value Sales
83.83x
TEVNet Income
-8.25x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
22.15%
Five Year Compounded Annual Growth Rate Of Revenue
9.69%
Non-Profit Donations & Grants
Investors
Details Hidden

Investor at Alnylam Pharmaceuticals, Inc.

Details Hidden

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Details Hidden

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

University of British Columbia Schools & Student Services | VANCOUVER, BRITISH COLUMBIA

The University of British Columbia (UBC), established in 1908, is one of Canada’s leading research universities and is consistently ranked among the top 40 in the world. The university attracts 54,000 students from across Canada and 140 countries around the world to two major campuses.

Massachusetts Institute of Technology Hospitals & Patient Services | CAMBRIDGE, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Synlogic, Inc. Biotechnology - Cambridge, MA

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Awards & Honors
2009
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alnylam Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alnylam Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alnylam Pharmaceuticals, Inc..